[go: up one dir, main page]

WO1997047253A1 - Procedes et dispositifs reduisant l'angine de poitrine, accroissant la perfusion du myocarde et ameliorant le fonctionnement du coeur - Google Patents

Procedes et dispositifs reduisant l'angine de poitrine, accroissant la perfusion du myocarde et ameliorant le fonctionnement du coeur Download PDF

Info

Publication number
WO1997047253A1
WO1997047253A1 PCT/US1997/010024 US9710024W WO9747253A1 WO 1997047253 A1 WO1997047253 A1 WO 1997047253A1 US 9710024 W US9710024 W US 9710024W WO 9747253 A1 WO9747253 A1 WO 9747253A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
blood vessels
cardiac function
myocardial perfusion
angiogenic
Prior art date
Application number
PCT/US1997/010024
Other languages
English (en)
Inventor
Robert B. Fine
Original Assignee
Kriton Medical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kriton Medical, Inc. filed Critical Kriton Medical, Inc.
Priority to AU33085/97A priority Critical patent/AU3308597A/en
Publication of WO1997047253A1 publication Critical patent/WO1997047253A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A61B18/22Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor
    • A61B18/24Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor with a catheter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/00234Surgical instruments, devices or methods for minimally invasive surgery
    • A61B2017/00238Type of minimally invasive operation
    • A61B2017/00243Type of minimally invasive operation cardiac
    • A61B2017/00247Making holes in the wall of the heart, e.g. laser Myocardial revascularization
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/22Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22082Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00345Vascular system
    • A61B2018/00351Heart
    • A61B2018/00392Transmyocardial revascularisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/062Apparatus for the production of blood vessels made from natural tissue or with layers of living cells

Definitions

  • the field of this invention concerns methods and devices for the treatment of disorders related to decreased myocardial perfusion and cardiac function, and, in particular, methods and devices for reducing angina pain, enhancing myocardial perfusion and/or increasing cardiac function.
  • Various surgical and pharmaceutical procedures have been used to attempt to enhance myocardial perfusion and/or cardiac function.
  • One such procedure currently being evaluated in human clinical trials is transmyocardial laser revascularization (TMLR) in which a laser is directed to the heart and traverses the myocardium.
  • TMLR transmyocardial laser revascularization
  • TMLR transmyocardial laser revascularization
  • TMLR transmyocardial laser revascularization
  • TMLR as currently practiced has not shown success in all instances, however. Levels of success rates are also variable. In addition, some
  • SUMMARY OF THE INVENTION Methods and devices are disclosed for reducing angina pain, enhancing myocardial perfusion and/or increasing cardiac function.
  • the present invention is based on the novel recognition by the inventor that the administration to a patient of angiogenic substances capable of stimulating the growth of blood vessels in combination with TMLR procedures and/or procedures for forming channels in the myocardium, can improve the reduction of angina pain, the enhancement of myocardial perfusion and/or the increase in cardiac function currently associated with TMLR procedures.
  • the inventor has recognized that administering angiogenic substances in conjunction with TMLR procedures and/or procedures for forming channels in the myocardium can expand the pool of patients who would benefit from treatment to reduce angina, to enhance myocardial perfusion and/or to increase cardiac function.
  • Myocardial perfusion includes blood flow to the heart tissue including myocardium, sub-endocardium, endocardium, sub-epicardium, and/or epicardium.
  • Angiogenic substances include substances capable of stimulating the growth of blood vessels.
  • Channels include holes, lumens or passageways, and other perforations in the heart.
  • TMLR procedures include procedures for directing a beam of radiation to heart tissue.
  • methods for reducing angina pain, enhancing myocardial perfusion and/or increasing cardiac function include
  • the method can involve producing the radiation from a laser, such as a carbon dioxide laser or other radiation producing elements known to those of ordinary skill in the art; and/or forming at least one channel in the myocardium.
  • the channel forming step can include forming the channel to link epicardial and endocardial surfaces of the heart.
  • the method can also be employed in conjunction with implanting and or removing at least one ventricular assist device (VAD).
  • VADs hereinafter can include left, right or bi- ventricular assist devices.
  • the angiogenic substance capable of stimulating the growth of blood vessels in the patient can include an angiogenic growth factor.
  • the angiogenic growth factor can include vascular endothelial growth factor (VEGF) vascular permeability factor (VPF) in native and/or non-native forms.
  • VEGF vascular endothelial growth factor
  • VPF vascular permeability factor
  • the angiogenic growth factor also can include a fibroblast growth factor, such as a basic fibroblast growth factor (bFGF or FGF- 2), in native and/or non-native forms, and/or acidic fibroblast growth factor (aFGF or FGF-1), in native and/or non-native forms.
  • bFGF or FGF-2 basic fibroblast growth factor
  • aFGF or FGF-1 acidic fibroblast growth factor
  • angiogenic substances include, but are not limited to, platelet-derived growth factor (PDGF) such as PDGF-AA, PDGF-BB, and PDGF-AB; hepatocyte growth factor/scatter factor (HGF/SF); placenta growth factor; endothelial cell growth factor (ECGF); platelet-derived endothelial cell growth factor (PD-ECGF); and urokinase plasminogen activator (uPA).
  • PDGF platelet-derived growth factor
  • HGF/SF hepatocyte growth factor/scatter factor
  • ECGF endothelial cell growth factor
  • PD-ECGF platelet-derived endothelial cell growth factor
  • uPA urokinase plasminogen activator
  • the angiogenic substance can be administered to the patient in a variety of ways.
  • methods of administering the angiogenic substance include one or more of the following steps; directly injecting the angiogenic substance into the atria, the ventricles, the veins, the arteries, and/or the formed channels; applying a slow-release formulation of the angiogenic substance into the formed channels; administering a slow-release formulation of the angiogenic substance orally, and/or via a skin patch; applying a material, such as a biologically compatible or incompatible, resorbable or non-resorbable material, contacted with the angiogenic substance, over the surface of the heart; and infusing the angiogenic substance into the patient via a pump connected to the atria, the ventricles, the veins, the arteries, and/or the formed channels.
  • methods of administering the angiogenic substance include one or more of the following steps: implanting a catheter, such as a slow-release catheter, contacted with the angiogenic substance, into the atria, the ventricles, and/or the formed channels; loading a sleeve, such as an infusion sleeve, contacted with the angiogenic substance, over a catheter and introducing the catheter into the formed channels; applying bead carriers, such as heparin- alginate beads, contacted with the angiogenic substance, over the epicardial and/or endocardial surfaces of the heart; inserting an implant, such as a fibrin-glue implant, contacted with the angiogenic substance, between, for example, the aorta and the myocardium, and/or in other positions of the epicardial and/or endocardial surfaces; injecting retroviral and/or non-retroviral vectors enclosing a gene for the angiogenic substance into the myocardi
  • methods for reducing angina pain, and/or enhancing myocardial perfusion and/or cardiac function include forming at least one channel in the myocardium of a patient, and administering to the
  • the channel forming step can include forming the channel to link epicardial and endocardial surfaces of the heart.
  • the method can also be employed in conjunction with implanting and/or removing a VAD.
  • the angiogenic substances and/or methods for administering the same discussed above can be used.
  • methods for reducing angina pain, and/or enhancing myocardial perfusion and/or cardiac function include forming at least one channel in the myocardium of the patient, and inserting into the channel at least one stent contacted with one or a mixture of angiogenic
  • the stent can be biologically compatible or incompatible, and the channel forming step can include forming the channel to link epicardial and endocardial surfaces of the heart.
  • the method can also include implanting and/or removing a VAD.
  • the angiogenic substances and/or methods for administering the same discussed above can be used with these aspects of the invention.
  • devices for reducing angina pain, and/or enhancing the myocardial perfusion and/or cardiac function of a patient include a stent contacted with at least one angiogenic substance capable of stimulating the growth of blood vessels in the patient and adapted for insertion into a channel formed in a myocardium of the heart of the patient.
  • the stent can be biologically compatible or non-compatible, resorbable or non-resorbable.
  • the devices of the invention can be self-expanding; and/or can further include an element for expanding the stent from a first to a second position.
  • the angiogenic substances discussed above can be used in these aspects of the invention.
  • devices for reducing angina in a patient and/or enhancing the myocardial perfusion and/or cardiac function of a patient include an element for directing a selected beam of radiation for a pre-determined time period to a heart of the patient, and an element for administering to the patient at least one angiogenic substance capable of stimulating growth of blood vessels in the patient.
  • the angiogenic substances discussed above can be used in these aspects of the invention.
  • devices for reducing angina in a patient and/or enhancing the myocardial perfusion and/or cardiac function of a patient include an element for forming at least one channel in a myocardium in a heart of the patient, and an element for administering to the patient at least one angiogenic substance capable of stimulating growth of blood vessels in the patient.
  • the angiogenic substances discussed above can be used in these aspects of the invention.
  • the present invention benefits from the recognition that TMLR procedures and/or procedures for forming channels in the myocardium can be performed in conjunction with the administration of angiogenic substances capable of stimulating the growth of blood vessels in a patient.
  • the methods and devices of the present invention have several advantages over the prior art.
  • the present invention can improve in patients the level of angina pain reduction, and/or enhance myocardial perfusion and/or cardiac function. Accordingly, the present invention can improve the treatment of disorders associated with reduced myocardial perfusion such as angina and/or improve cardiac functions in patients experiencing different levels of heart failure. In addition, the present invention can expand the pool of patients who can be eligible for TMLR procedures and/or procedures involving the formation of channels in the myocardium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Electromagnetism (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un procédé et un appareil traitant les troubles liés à une baisse de la perfusion du myocarde et du fonctionnement du coeur. Un faisceau de rayons sélectionnés est dirigé sur le coeur du patient pendant un temps prédéterminé puis un angiogène susceptible de stimuler le développement des vaisseaux sanguins du patient lui est administré.
PCT/US1997/010024 1996-06-14 1997-06-11 Procedes et dispositifs reduisant l'angine de poitrine, accroissant la perfusion du myocarde et ameliorant le fonctionnement du coeur WO1997047253A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33085/97A AU3308597A (en) 1996-06-14 1997-06-11 Methods and devices for reducing angina, enhancing myocardial perfusion and increasing cardiac function

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2048296P 1996-06-14 1996-06-14
US60/020,482 1996-06-14

Publications (1)

Publication Number Publication Date
WO1997047253A1 true WO1997047253A1 (fr) 1997-12-18

Family

ID=21798856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/010024 WO1997047253A1 (fr) 1996-06-14 1997-06-11 Procedes et dispositifs reduisant l'angine de poitrine, accroissant la perfusion du myocarde et ameliorant le fonctionnement du coeur

Country Status (2)

Country Link
AU (1) AU3308597A (fr)
WO (1) WO1997047253A1 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925012A (en) * 1996-12-27 1999-07-20 Eclipse Surgical Technologies, Inc. Laser assisted drug delivery
WO1999039624A1 (fr) * 1998-02-05 1999-08-12 Biosense Inc. Administration de medicament intracardiaque
US5999678A (en) * 1996-12-27 1999-12-07 Eclipse Surgical Technologies, Inc. Laser delivery means adapted for drug delivery
US6067988A (en) * 1996-12-26 2000-05-30 Eclipse Surgical Technologies, Inc. Method for creation of drug delivery and/or stimulation pockets in myocardium
US6152141A (en) * 1994-07-28 2000-11-28 Heartport, Inc. Method for delivery of therapeutic agents to the heart
US6251079B1 (en) 1998-09-30 2001-06-26 C. R. Bard, Inc. Transthoracic drug delivery device
US6254573B1 (en) 1998-02-05 2001-07-03 Biosense, Inc. Intracardiac drug delivery device utilizing spring-loaded mechanism
US6551302B1 (en) 1997-09-24 2003-04-22 Michael J. Rosinko Steerable catheter with tip alignment and surface contact detector
US6591129B1 (en) 1996-02-15 2003-07-08 Biosense, Inc. Method for treating tissue through injection of a therapeutic agent
US6676679B1 (en) 1999-11-05 2004-01-13 Boston Scientific Corporation Method and apparatus for recurrent demand injury in stimulating angiogenesis
US6695808B2 (en) 2000-03-23 2004-02-24 Scimed Life Systems, Inc. Pressure sensor for therapeutic delivery device and method
US6748258B1 (en) 1999-11-05 2004-06-08 Scimed Life Systems, Inc. Method and devices for heart treatment
US6746686B2 (en) 2000-01-24 2004-06-08 Biocompatibles Uk Limited Coated implants
US6855160B1 (en) 1999-08-04 2005-02-15 C. R. Bard, Inc. Implant and agent delivery device
US6949117B2 (en) 1998-09-30 2005-09-27 C. R. Bard, Inc. Vascular inducing implants
US6986784B1 (en) 1999-05-14 2006-01-17 C. R. Bard, Inc. Implant anchor systems
US7147633B2 (en) 1999-06-02 2006-12-12 Boston Scientific Scimed, Inc. Method and apparatus for treatment of atrial fibrillation
US7204847B1 (en) 2000-07-28 2007-04-17 C. R. Bard, Inc. Implant anchor systems
US7214223B2 (en) 2000-03-24 2007-05-08 Boston Scientific Scimed, Inc. Photoatherolytic catheter apparatus and method
US7232421B1 (en) 2000-05-12 2007-06-19 C. R. Bard, Inc. Agent delivery systems
EP1753451A4 (fr) * 2004-06-07 2008-11-12 Conor Medsystems Inc Apport local de facteurs de croissance pour la transplantation de cellules souches
US7588554B2 (en) 2000-06-26 2009-09-15 Boston Scientific Scimed, Inc. Method and apparatus for treating ischemic tissue

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5287861A (en) * 1992-10-30 1994-02-22 Wilk Peter J Coronary artery by-pass method and associated catheter
US5429144A (en) * 1992-10-30 1995-07-04 Wilk; Peter J. Coronary artery by-pass method
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5527337A (en) * 1987-06-25 1996-06-18 Duke University Bioabsorbable stent and method of making the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527337A (en) * 1987-06-25 1996-06-18 Duke University Bioabsorbable stent and method of making the same
US5287861A (en) * 1992-10-30 1994-02-22 Wilk Peter J Coronary artery by-pass method and associated catheter
US5429144A (en) * 1992-10-30 1995-07-04 Wilk; Peter J. Coronary artery by-pass method
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMERICAN HEART JOURNAL, September 1983, Volume 106, Number 3, LEE et al., "Effects of Laser Irradiation Delivered by Flexible Fiberoptic System on the Left Ventricular Internal Myocardium", pages 587-590. *
IEEE JOURNAL OF QUANTUM ELECTRONICS, December 1984, Vol. QE-20, No. 12, ISNER et al., "The Current Status of Lasers in Treatment of Cardiovascular Disease", pages 1406-1420. *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6152141A (en) * 1994-07-28 2000-11-28 Heartport, Inc. Method for delivery of therapeutic agents to the heart
US6591129B1 (en) 1996-02-15 2003-07-08 Biosense, Inc. Method for treating tissue through injection of a therapeutic agent
US6067988A (en) * 1996-12-26 2000-05-30 Eclipse Surgical Technologies, Inc. Method for creation of drug delivery and/or stimulation pockets in myocardium
US6482220B1 (en) 1996-12-26 2002-11-19 Eclipse Surgical Technologies Inc. Method and apparatus for creation of drug delivery and/or stimulation pockets in myocardium
US5999678A (en) * 1996-12-27 1999-12-07 Eclipse Surgical Technologies, Inc. Laser delivery means adapted for drug delivery
US5925012A (en) * 1996-12-27 1999-07-20 Eclipse Surgical Technologies, Inc. Laser assisted drug delivery
US6551302B1 (en) 1997-09-24 2003-04-22 Michael J. Rosinko Steerable catheter with tip alignment and surface contact detector
WO1999039624A1 (fr) * 1998-02-05 1999-08-12 Biosense Inc. Administration de medicament intracardiaque
US6254573B1 (en) 1998-02-05 2001-07-03 Biosense, Inc. Intracardiac drug delivery device utilizing spring-loaded mechanism
US6309370B1 (en) 1998-02-05 2001-10-30 Biosense, Inc. Intracardiac drug delivery
US6733488B2 (en) 1998-09-30 2004-05-11 C.R. Bard, Inc. Transthoracic drug delivery device
US6251079B1 (en) 1998-09-30 2001-06-26 C. R. Bard, Inc. Transthoracic drug delivery device
US6517527B2 (en) 1998-09-30 2003-02-11 C. R. Bard, Inc. Transthoracic drug delivery device
US6949117B2 (en) 1998-09-30 2005-09-27 C. R. Bard, Inc. Vascular inducing implants
US6986784B1 (en) 1999-05-14 2006-01-17 C. R. Bard, Inc. Implant anchor systems
US7147633B2 (en) 1999-06-02 2006-12-12 Boston Scientific Scimed, Inc. Method and apparatus for treatment of atrial fibrillation
US6855160B1 (en) 1999-08-04 2005-02-15 C. R. Bard, Inc. Implant and agent delivery device
US6748258B1 (en) 1999-11-05 2004-06-08 Scimed Life Systems, Inc. Method and devices for heart treatment
US6676679B1 (en) 1999-11-05 2004-01-13 Boston Scientific Corporation Method and apparatus for recurrent demand injury in stimulating angiogenesis
US7392077B2 (en) 1999-11-05 2008-06-24 Boston Scientific Scimed, Inc. Method for treating a patient at risk of loss of cardiac function by cardiac ischemia
US6746686B2 (en) 2000-01-24 2004-06-08 Biocompatibles Uk Limited Coated implants
US6695808B2 (en) 2000-03-23 2004-02-24 Scimed Life Systems, Inc. Pressure sensor for therapeutic delivery device and method
US7211063B2 (en) 2000-03-23 2007-05-01 Boston Scientific Scimed, Inc. Pressure sensor for therapeutic delivery device and method
US7214223B2 (en) 2000-03-24 2007-05-08 Boston Scientific Scimed, Inc. Photoatherolytic catheter apparatus and method
US7232421B1 (en) 2000-05-12 2007-06-19 C. R. Bard, Inc. Agent delivery systems
US7588554B2 (en) 2000-06-26 2009-09-15 Boston Scientific Scimed, Inc. Method and apparatus for treating ischemic tissue
US7204847B1 (en) 2000-07-28 2007-04-17 C. R. Bard, Inc. Implant anchor systems
EP1753451A4 (fr) * 2004-06-07 2008-11-12 Conor Medsystems Inc Apport local de facteurs de croissance pour la transplantation de cellules souches

Also Published As

Publication number Publication date
AU3308597A (en) 1998-01-07

Similar Documents

Publication Publication Date Title
WO1997047253A1 (fr) Procedes et dispositifs reduisant l'angine de poitrine, accroissant la perfusion du myocarde et ameliorant le fonctionnement du coeur
US6585716B2 (en) Method of treating the heart
US5797870A (en) Pericardial delivery of therapeutic and diagnostic agents
US6224584B1 (en) Therapeutic and diagnostic agent delivery
US5840059A (en) Therapeutic and diagnostic agent delivery
US7033372B1 (en) Corkscrew reinforced left ventricle to coronary artery channel
US6224566B1 (en) Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium
JP4224608B2 (ja) 注入療法用装置
US6508783B2 (en) Ultrasound method for revascularization and drug delivery
US20030181843A1 (en) Device and method providing arterial blood flow for perfusion of ischemic myocardium
US20100179643A1 (en) Device and method for treating ischemic heart disease
WO1999029251A1 (fr) Procede et appareil pour la liberation d'agents therapeutiques dans le coeur
US20020029037A1 (en) Method and apparatus for percutaneous trans-endocardial reperfusion
US5873366A (en) Method for transmyocardial revascularization
RU2026640C1 (ru) Способ хирургического лечения ишемической болезни сердца
JPH1033550A (ja) レーザ活用経心筋血管再生および他の用途のための深さ止め装置および方法
WO1998057591A1 (fr) Pontage cavite-artere percutane
Mack et al. Minimally invasive thoracoscopically assisted coronary artery bypass surgery
WO2001010340A1 (fr) Canal entre ventricule gauche et artere coronaire renforce par un serpentin
US6325813B1 (en) Method and apparatus for stabilizing vascular wall
Shawl et al. Procedural results and early clinical outcome of percutaneous transluminal myocardial revascularization
EP1188417A2 (fr) Procédé et dispositif pour l'administration d'agents thérapeutiques dans le coeur
SU1754128A1 (ru) Способ лечени ишемической болезни сердца
US20020121280A1 (en) Method for myocardial revascularization
JP2002538930A (ja) 心筋層横断の血管再構築のための加圧液体噴射の外科器具

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 98501769

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase